Shares in Novo Nordisk opened sharply lower on Wednesday, after the obesity drug specialist warned of thinning sales and profits.

European stocks edged lower at the open on Wednesday as investors digested the latest earnings dump and the threat to software stocks from the expanding tentacles of artificial intelligence which ...

By Maggie Fick and Jacob Gronholt-Pedersen LONDON/COPENHAGEN, Feb 4 (Reuters) - Novo Nordisk's shares plunged as much as 20% ...

Meanwhile, Novo Nordisk said Tuesday that fourth-quarter sales of Wegovy rose 17% on year at constant exchange rates to 21.86 billion Danish kroner ($3.46 billion), while sales of Ozempic rose 1% to ...

The company said on Tuesday that sales could fall by as much as 13% this year, News.Az reports, citing Bloomberg. It cited pressure from lower ...

Rolling coverage of the latest economic and financial news ...

Novo Nordisk expects a decline in sales of up to 13 per cent this year as the Danish drugmaker competes in an increasingly crowded obesity-treatment market and faces pressure on the pricing of its ...

Novo Nordisk’s stock plunged Tuesday after the maker of diabetes and weight-loss drugs Ozempic and Wegovy said it expects sales to fall by a lot more than analysts projected.

By Maggie Fick and Jacob Gronholt-Pedersen LONDON/COPENHAGEN, Feb 4 (Reuters) - Danish obesity drug giant Novo Nordisk is set ...

By Maggie Fick and Jacob Gronholt-Pedersen LONDON/COPENHAGEN, Feb 4 (Reuters) - Danish obesity drug giant Novo Nordisk is set ...

Just as Novo Nordisk showed signs of a recovery, another cold shower hit investors as the drugmaker surprise prereleased its ...

COPENHAGEN, Feb 3 (Reuters) - Wegovy maker Novo Nordisk warned on Tuesday that profits and sales could drop as much as 13% ...